Sophie Shifman
Overview
Explore the profile of Sophie Shifman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fang J, Hurley N, Chien C, Guo A, Khan T, Li M, et al.
J Chem Phys
. 2024 Jun;
160(23).
PMID: 38884404
Zinc tungstate is a semiconductor known for its favorable photocatalytic, photoluminescence, and scintillation properties, coupled with its relatively low cost, reduced toxicity, and high stability in biological and catalytic environments....
2.
Radin D, Shifman S, Outhwaite I, Sharma A, Bases R, Seeliger M, et al.
J Pharmacol Exp Ther
. 2024 Jan;
389(1):51-60.
PMID: 38296645
Glioblastoma (GBM) is the most frequently diagnosed primary central nervous system tumor in adults. Despite the standard of care therapy, which includes surgical resection, temozolomide chemotherapy, radiation and the newly...
3.
Rosen E, Won H, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al.
Nat Commun
. 2022 Apr;
13(1):1936.
PMID: 35383193
No abstract available.
4.
Rosen E, Won H, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al.
Nat Commun
. 2022 Mar;
13(1):1450.
PMID: 35304457
The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-driven cancers, and we sought to characterize the molecular determinants of response and resistance. We find that...
5.
Cocco E, Lee J, Kannan S, Schram A, Won H, Shifman S, et al.
Cancer Discov
. 2020 Oct;
11(1):126-141.
PMID: 33004339
On-target resistance to next-generation TRK inhibitors in TRK fusion-positive cancers is largely uncharacterized. In patients with these tumors, we found that TRK xDFG mutations confer resistance to type I next-generation...
6.
Li B, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, et al.
Cancer Discov
. 2020 Mar;
10(5):674-687.
PMID: 32213539
Amplification of and oncogenic mutations in , the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather...
7.
Yohn C, Shifman S, Garino A, Diethorn E, Bokka L, Ashamalla S, et al.
Psychopharmacology (Berl)
. 2020 Jan;
237(5):1281-1290.
PMID: 31965254
Rationale: Some mood disorders, such as major depressive disorder, are more prevalent in women than in men. However, historically preclinical studies in rodents have a lower inclusion rate of females...
8.
Rosen E, Goldman D, Hechtman J, Benayed R, Schram A, Cocco E, et al.
Clin Cancer Res
. 2019 Dec;
26(7):1624-1632.
PMID: 31871300
Purpose: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to...
9.
Cocco E, Schram A, Kulick A, Misale S, Won H, Yaeger R, et al.
Nat Med
. 2019 Aug;
25(9):1422-1427.
PMID: 31406350
TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition. With the recent approval of the first selective...